Skip to main content
. 2020 Aug 13;28:139–148. doi: 10.1016/j.jare.2020.08.005

Fig. 4.

Fig. 4

D1DR/D2DR antagonists inhibited Src to suppress NMDAR and downstream MAPKs to attenuate bone cancer pain. (a) The mechanical thresholds of TCI rats after administration of Src inhibitor PP2 or coadministration of Src inhibitor PP2 with NMDA (n = 6, * P < 0.05, ** P < 0.01, compared with 0 h, # P < 0.05, ## P < 0.01, compared with TCI + Src inhibitor group, & P < 0.05, && P < 0.01, compared with Sham + Vehicle group, Vehicle: 2% DMSO) (NMDA was administered 30 min before PP2 treatment). (b) The p-Src expression in TCI rats after administration of SCH 23390/L-741,626. (c, d, e) The p-p38, p-ERK, and p-JNK expression in TCI rats after coadministration of Src inhibitor PP2 with NMDA. (n = 4, # P < 0.05, ## P < 0.01, compared with control group, *P < 0.05, ** P < 0.01, compared with TCI + Vehicle group, & P < 0.05, && P < 0.01, compared with TCI + Src inhibitor group, p-Src/Src is the expression of (p-Src/GAPDH)/(Src/GAPDH), p-MAPKs/MAPKs is the expression of (p- MAPKs/GAPDH)/(MAPKs/GAPDH)).